Federico Innocenti

Federico Innocenti

UNVERIFIED PROFILE

Are you Federico Innocenti?   Register this Author

Register author
Federico Innocenti

Federico Innocenti

Publications by authors named "Federico Innocenti"

Are you Federico Innocenti?   Register this Author

100Publications

1892Reads

36Profile Views

Reply to S. Sorscher.

J Clin Oncol 2019 Sep 3;37(25):2291-2293. Epub 2019 Jul 3.

Federico Innocenti, MD, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC; Fang-Shu Ou, PhD, Mayo Clinic Minnesota, Rochester, MN; Xueping Qu, PhD, Genentech, South San Francisco, CA; Tyler Zemla, MS, Mayo Clinic Minnesota, Rochester, MN; Donna Niedzwiecki, PhD, Duke University, Durham, NC; Rachel Tam, PhD and Shilpi Mahajan, PhD, Genentech, South San Francisco, CA; Richard M. Goldberg, MD, West Virginia University Cancer Institute, Morgantown, WV; Monica M. Bertagnolli, MD, Dana-Farber Cancer Institute, Boston, MA; Charles David Blanke, MD, Oregon Health and Science University Hospital, Portland, OR; Hanna Sanoff, MD, University of North Carolina at Chapel Hill, Chapel Hill, NC; James Atkins, MD, Bon Secours Health System, Richmond, VA; Blasé Polite, MD, University of Chicago Medical Center, Chicago, IL; Alan P. Venook, MD, University of California San Francisco, San Francisco, CA; Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA; and Omar Kabbarah, PhD, ORIC Pharmaceuticals, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01366DOI Listing
September 2019

fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies.

BMC Bioinformatics 2019 Jun 13;20(1):333. Epub 2019 Jun 13.

Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12859-019-2869-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567636PMC
June 2019

Genetic Variants of and Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib.

Cancer Res 2019 01 1;79(1):231-241. Epub 2018 Nov 1.

Division of Pharmacotherapy and Experimental Therapeutics, Center for Pharmacogenomics and Individualized Therapy, The University of North Carolina Eshelman School of Pharmacy, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-1089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541205PMC
January 2019

Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine.

Am J Pharm Educ 2018 08;82(6):6652

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5688/ajpe6652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116878PMC
August 2018

Reply to L. Casadaban et al.

J Clin Oncol 2017 04 23;35(12):1373-1374. Epub 2017 Jan 23.

Donna Niedzwiecki, Duke University, Durham, NC; Wendy L. Frankel, The Ohio State University, Columbus, OH; Alan P. Venook, University of California, San Francisco, San Francisco, CA; Xing Ye, Duke University, Durham, NC; Paula N. Friedman, Northwestern University, Chicago, IL; Richard M. Goldberg, The Ohio State University, Columbus, OH; Robert J. Mayer, Dana-Farber Cancer Institute, Boston, MA; Thomas A. Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, and Peter Kerr, Almac Diagnostics, Craigavon, United Kingdom; Patrick G. Johnston, Queen's University, Belfast, United Kingdom; Richard D. Kennedy and D. Paul Harkin, Almac Diagnostics, Craigavon, United Kingdom; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Robert S. Warren, University of California, San Francisco, San Francisco, CA; and Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.2646
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.2646DOI Listing
April 2017

Bringing a genomic perspective to the safety of drug treatment in oncology.

F1000Res 2017 29;6. Epub 2017 Mar 29.

Eshelman School of Pharmacy, Center for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12688/f1000research.10475.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373416PMC
March 2017

Genomic Characterization of Metformin Hepatic Response.

PLoS Genet 2016 Nov 30;12(11):e1006449. Epub 2016 Nov 30.

Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pgen.1006449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130177PMC
November 2016

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

J Clin Oncol 2016 09 18;34(25):3047-53. Epub 2016 Jul 18.

Donna Niedzwiecki and Xing Ye, Duke University, Durham; Federico Innocenti, University of North Carolina at Chapel Hill, Chapel Hill, NC; Wendy L. Frankel and Richard M. Goldberg, The Ohio State University, Columbus, OH; Alan P. Venook and Robert S. Warren, University of California-San Francisco, San Francisco, CA; Paula N. Friedman, The University of Chicago, Chicago, IL; Robert J. Mayer, Dana-Farber Cancer Institute; Monica M. Bertagnolli, Brigham and Women's Hospital, Boston, MA; Thomas Anthony Colacchio, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jude Marie Mulligan, Timothy S. Davison, Eamonn O'Brien, Peter Kerr, Richard D. Kennedy, and D. Paul Harkin, Almac Diagnostics, Craigavon; Patrick G. Johnston, Queen's University, Belfast, Northern Ireland; and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.4699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012711PMC
September 2016

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

J Clin Oncol 2016 08 2;34(22):2602-9. Epub 2016 May 2.

Maura N. Dickler, Mary Ellen Moynahan, Diana E. Lake, and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; William T. Barry, Dana-Farber Cancer Institute; Eric P. Winer, Dana-Farber/Partners Cancer Care, Boston, MA; Constance T. Cirrincione, Duke University, Durham, NC; Matthew J. Ellis, Baylor College of Medicine; Debasish Tripathy, The University of Texas MD Anderson Cancer Center, Houston, TX; Federico Innocenti and Lisa A. Carey, University of North Carolina at Chapel Hill, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte; Hope S. Rugo, University of California at San Francisco, San Francisco, CA; Olwen Hahn, Alliance for Clinical Trials in Oncology, Chicago, IL; and Bryan P. Schneider, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690PMC
August 2016

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

Pharmacogenet Genomics 2015 Dec;25(12):573-83

aPharmacogenomics Laboratory, Centre Hospitalier Universitaire de Québec (CHU de Québec) Research Center and Faculty of Pharmacy bCHU de Québec Research Center and Faculty of Medicine, Laval University cCanada Research Chair in Pharmacogenomics, CHU de Québec Research Center, Québec, Canada dDepartment of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada eDepartment of Molecular Biology and Translational Research, Division of Experimental and Clinical Pharmacology, National Cancer Institute and Cancer for Molecular Biomedicine, Aviano, Italy fEshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/FPC.0000000000000168DOI Listing
December 2015

Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jul;10(7):1067-75

*Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina; †Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Australia; ‡Department of Genetics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; §Molecular Oncology Laboratory, General University Hospital Research Foundation, Valencia, Spain; ‖Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina; ¶Department of Medicine, University of Chicago, Chicago, Illinois; #Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois; **Department of Thoracic Surgery, and ††Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; ‡‡Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado; §§Department of Medicine, University of Valencia, Valencia, Spain; ‖‖Department of Oncology, General University Hospital of Valencia, Valencia, Spain; and ¶¶Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000549DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494119PMC
July 2015

Hidden Markov Model-Based CNV Detection Algorithms for Illumina Genotyping Microarrays.

Cancer Inform 2014 27;13(Suppl 7):77-83. Epub 2015 Jan 27.

Center for Pharmacogenomics and Individualized Therapy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. ; UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/CIN.S16345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310714PMC
February 2015

DPYD variants to predict 5-FU toxicity: the ultimate proof.

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Nov 7.

Eshelman School of Pharmacy, Center for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju351DOI Listing
December 2014

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.

Authors:
Brian M Wolpin Cosmeri Rizzato Peter Kraft Charles Kooperberg Gloria M Petersen Zhaoming Wang Alan A Arslan Laura Beane-Freeman Paige M Bracci Julie Buring Federico Canzian Eric J Duell Steven Gallinger Graham G Giles Gary E Goodman Phyllis J Goodman Eric J Jacobs Aruna Kamineni Alison P Klein Laurence N Kolonel Matthew H Kulke Donghui Li Núria Malats Sara H Olson Harvey A Risch Howard D Sesso Kala Visvanathan Emily White Wei Zheng Christian C Abnet Demetrius Albanes Gabriella Andreotti Melissa A Austin Richard Barfield Daniela Basso Sonja I Berndt Marie-Christine Boutron-Ruault Michelle Brotzman Markus W Büchler H Bas Bueno-de-Mesquita Peter Bugert Laurie Burdette Daniele Campa Neil E Caporaso Gabriele Capurso Charles Chung Michelle Cotterchio Eithne Costello Joanne Elena Niccola Funel J Michael Gaziano Nathalia A Giese Edward L Giovannucci Michael Goggins Megan J Gorman Myron Gross Christopher A Haiman Manal Hassan Kathy J Helzlsouer Brian E Henderson Elizabeth A Holly Nan Hu David J Hunter Federico Innocenti Mazda Jenab Rudolf Kaaks Timothy J Key Kay-Tee Khaw Eric A Klein Manolis Kogevinas Vittorio Krogh Juozas Kupcinskas Robert C Kurtz Andrea LaCroix Maria T Landi Stefano Landi Loic Le Marchand Andrea Mambrini Satu Mannisto Roger L Milne Yusuke Nakamura Ann L Oberg Kouros Owzar Alpa V Patel Petra H M Peeters Ulrike Peters Raffaele Pezzilli Ada Piepoli Miquel Porta Francisco X Real Elio Riboli Nathaniel Rothman Aldo Scarpa Xiao-Ou Shu Debra T Silverman Pavel Soucek Malin Sund Renata Talar-Wojnarowska Philip R Taylor George E Theodoropoulos Mark Thornquist Anne Tjønneland Geoffrey S Tobias Dimitrios Trichopoulos Pavel Vodicka Jean Wactawski-Wende Nicolas Wentzensen Chen Wu Herbert Yu Kai Yu Anne Zeleniuch-Jacquotte Robert Hoover Patricia Hartge Charles Fuchs Stephen J Chanock Rachael S Stolzenberg-Solomon Laufey T Amundadottir

Nat Genet 2014 Sep 3;46(9):994-1000. Epub 2014 Aug 3.

1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. [2].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.3052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191666PMC
September 2014

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

J Clin Oncol 2014 Aug 23;32(22):2328-34. Epub 2014 Jun 23.

Federico Innocenti, Richard L. Schilsky, Jacqueline Ramírez, Linda Janisch, Samir Undevia, Larry K. House, Soma Das, Kehua Wu, Michelle Turcich, Theodore Karrison, Michael L. Maitland, Ravi Salgia, and Mark J. Ratain, University of Chicago, Chicago; and Robert Marsh, NorthShore University Health System, Evanston, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2307DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105486PMC
August 2014

25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).

J Natl Cancer Inst 2014 Aug 6;106(8). Epub 2014 Aug 6.

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA (KVL, APV); Department of Biostatistics and Bioinformatics, Duke University, Durham, NC (KO, DN); Alliance Statistics and Data Center, Duke University, Durham, NC (KO, CJ, DN); The University of Chicago Medical Center, Chicago, IL (HLK); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL (MFM); Memorial Sloan-Kettering Cancer Center, New York, NY (EMO); Dana-Farber Cancer Institute, Boston, MA (CF); University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, School of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, NC (FI).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155431PMC
August 2014

Genomics into Healthcare: the 5th Pan Arab Human Genetics Conference and 2013 Golden Helix Symposium.

Hum Mutat 2014 May 31;35(5):637-40. Epub 2014 Mar 31.

Cancer Genomics Laboratory, Kimmel Cancer Center, Department of Cancer Biology, Thomas Jefferson University Jefferson Medical College, Philadelphia, Pennsylvania; Department of Molecular Medicine, Universita' La Sapienza, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.22530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128335PMC
May 2014

A guide to the current Web-based resources in pharmacogenomics.

Methods Mol Biol 2013 ;1015:293-310

Queensland Institute of Medical Research, Brisbane, QLD, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-435-7_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795434PMC
February 2014

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

Pharmacogenet Genomics 2014 Feb;24(2):129-32

aDepartment of Medicine, The University of Chicago, Chicago, Illinois bDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901533PMC
February 2014

Implications of genome-wide association studies in cancer therapeutics.

Br J Clin Pharmacol 2013 Sep;76(3):370-80

UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, 27599-7361, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.12166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769665PMC
September 2013

Liver expression quantitative trait loci: a foundation for pharmacogenomic research.

Front Genet 2012 14;3:153. Epub 2012 Aug 14.

Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fgene.2012.00153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418580PMC
October 2012

The influence of UGT polymorphisms as biomarkers in solid organ transplantation.

Clin Chim Acta 2012 Sep 1;413(17-18):1318-25. Epub 2012 Feb 1.

University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, NC 27599-7569, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2012.01.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795433PMC
September 2012

Moving away from candidate genes: a 'genome-wise' discovery of gemcitabine myelotoxicity.

Pharmacogenomics 2012 Jul;13(10):1113-4

University of North Carolina at Chapel Hill, Institute for Pharmacogenomics & Individualized Therapy, Eshelman School of Pharmacy, School of Medicine, Chapel Hill, NC 27599-7361, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.12.96DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131678PMC
July 2012

One SNP for both cancer risk and survival in colorectal cancer: two for the price of one?

Pharmacogenomics 2012 Jul;13(10):1114

University of North Carolina at Chapel Hill, Institute for Pharmacogenomics & Individualized Therapy, Eshelman School of Pharmacy, School of Medicine, Chapel Hill, NC 27599-7361, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128334PMC
July 2012

Systemic therapies for pancreatic cancer--the role of pharmacogenetics.

Curr Drug Targets 2012 Jun;13(6):811-28

Department of Hematology-Oncology, National University Health System, Singapore.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795429PMC
http://dx.doi.org/10.2174/138945012800564068DOI Listing
June 2012

Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Biomark Med 2012 Jun;6(3):349-62

Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm.12.19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704209PMC
June 2012

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.

Cancer Chemother Pharmacol 2011 Dec 23;68(6):1629-32. Epub 2011 Aug 23.

Department of Medicine, Section of Hematology/Oncology, University of Chicago, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-011-1727-4
Publisher Site
http://dx.doi.org/10.1007/s00280-011-1727-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259680PMC
December 2011

Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Clin Chem Lab Med 2011 Oct 28;49(10):1621-32. Epub 2011 Sep 28.

Department of Hematology-Oncology, National University Cancer Institute, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/CCLM.2011.715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858908PMC
October 2011

Mechanisms of genetic regulation in gene expression: examples from drug metabolizing enzymes and transporters.

Wiley Interdiscip Rev Syst Biol Med 2011 May-Jun;3(3):299-313. Epub 2010 Sep 23.

Department of Medicine, University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/wsbm.125DOI Listing
July 2011

Genetic Analysis in Translational Medicine: The 2010 GOLDEN HELIX Symposium.

Hum Mutat 2011 Jun 24;32(6):698-703. Epub 2011 Mar 24.

University of Patras, School of Health Sciences, Department of Pharmacy, Patras, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.21473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795430PMC
June 2011

The use of genomic information to optimize cancer chemotherapy.

Semin Oncol 2011 Apr;38(2):186-95

Department of Medicine, Comprehensive Cancer Center, The University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2011.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076508PMC
April 2011

Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Future Oncol 2010 Apr;6(4):563-85

Department of Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.10.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102300PMC
April 2010

Pharmacogenomics: paving the path to personalized medicine.

Pharmacogenomics 2010 Feb;11(2):141-6

University of Patras, School of Health Sciences, Department of Pharmacy, University Campus, GR-26504, Rion, Patras, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.09.174DOI Listing
February 2010

Translating the cancer genome into clinically useful tools and strategies.

Dis Model Mech 2009 Sep-Oct;2(9-10):426-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1242/dmm.004119DOI Listing
January 2010

Individualizing dosing of irinotecan.

Clin Cancer Res 2010 Jan 12;16(2):371-2. Epub 2010 Jan 12.

Section of Hematology/Oncology, Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, The University of Chicago, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2936DOI Listing
January 2010

Clinical pharmacology and pharmacogenetics of gemcitabine.

Drug Metab Rev 2009 ;41(2):77-88

Department of Hematology-Oncology, National University Hospital, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03602530902741828DOI Listing
September 2009

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

Eur J Cancer 2009 Jul 21;45(11):1904-8. Epub 2009 May 21.

Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2009.04.032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758059PMC
July 2009

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Pharmacogenomics 2009 Jul;10(7):1139-46

UNC Institute for Pharmacogenomics & Individualized Therapy, University of North Carolina, Genetic Medicine Building, Chapel Hill, NC 27599-7360, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/pgs.09.35
Publisher Site
http://dx.doi.org/10.2217/pgs.09.35DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748108PMC
July 2009

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

Pharmacotherapy 2008 Jun;28(6):755-68

Sections of Genetic Medicine, Department of Medicine, University of Chicago, Chicago, Illinois, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1592/phco.28.6.755DOI Listing
June 2008

Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.

Drug Metab Dispos 2007 Dec 30;35(12):2149-53. Epub 2007 Aug 30.

Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.107.015446DOI Listing
December 2007

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.

Cancer Chemother Pharmacol 2007 Nov 17;60(6):811-9. Epub 2007 Feb 17.

Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-007-0428-5DOI Listing
November 2007

Role of UGT1A1*6 in irinogenetics in Asians.

Per Med 2007 Nov;4(4):431-434

University of Chicago, Department of Medicine, Section of Hematology-Oncology, 5841 S. Maryland Avenue, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/17410541.4.4.431DOI Listing
November 2007

Translation of pharmacogenetic knowledge into cancer therapeutics.

Clin Adv Hematol Oncol 2007 Sep;5(9):698-706

Department of Haematology-Oncology, National University Hospital, Singapore 119074.

View Article

Download full-text PDF

Source
September 2007

UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.

Pharmacogenet Genomics 2007 Aug;17(8):619-27

Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e3280121fe9DOI Listing
August 2007

Insights, challenges, and future directions in irinogenetics.

Ther Drug Monit 2007 Jun;29(3):265-70

Section of Oncology, Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FTD.0b013e318068623bDOI Listing
June 2007

Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.

PLoS One 2007 Apr 25;2(4):e396. Epub 2007 Apr 25.

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0000396PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1851988PMC
April 2007

Effects of green tea compounds on irinotecan metabolism.

Drug Metab Dispos 2007 Feb 15;35(2):228-33. Epub 2006 Nov 15.

Department of Medicine, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.106.012047DOI Listing
February 2007

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

J Clin Pharmacol 2007 Jan;47(1):78-86

Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, WO21 Rm 3667, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1177/0091270006295060
Publisher Site
http://dx.doi.org/10.1177/0091270006295060DOI Listing
January 2007

Challenges in the development and use of pharmacogenomic markers in oncology.

J Support Oncol 2007 Jan;5(1):15-6

Section of Hematology/Oncology, Department of Medicine, Cancer Research Center, University of Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

Source
January 2007

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.

Pharmacogenomics 2006 Dec;7(8):1211-21

The University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Chicago, IL, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/14622416.7.8.1211
Publisher Site
http://dx.doi.org/10.2217/14622416.7.8.1211DOI Listing
December 2006

The role of pharmacogenetics in cancer therapeutics.

Br J Clin Pharmacol 2006 Jul;62(1):35-46

University of Chicago, Committee on Clinical Pharmacology and Pharmacogenomics, Department of Medicine and Cancer Research Center, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2006.02591.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885075PMC
July 2006

MTHFR and ALL risk: a challenge.

Leuk Lymphoma 2006 Jul;47(7):1203-4

Experimental and Clinical Pharmacology Unit, CRO National Cancer Institute, Aviano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190600725461DOI Listing
July 2006

Irinogenetics: what is the right star?

J Clin Oncol 2006 May 24;24(15):2221-4. Epub 2006 Apr 24.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.05.2464DOI Listing
May 2006

UGT1A1 genotyping in patients undergoing treatment with irinotecan.

Clin Adv Hematol Oncol 2005 Nov;3(11):843-4

University of Chicago, USA.

View Article

Download full-text PDF

Source
November 2005

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.

Clin Cancer Res 2005 Sep;11(18):6699-704

Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0703DOI Listing
September 2005